Issuance Of New US Patent Bolsters IP Protection For Jaguar Health In The Treatment Of Short Bowel Syndrome
Portfolio Pulse from Benzinga Newsdesk
Jaguar Health (NASDAQ:JAGX) has been granted a new U.S. patent for methods of treating short bowel syndrome (SBS), bile acid diarrhea, and diarrhea associated with small intestine resection or gallbladder removal, using crofelemer, a novel plant-based prescription drug. The company is supporting studies of crofelemer for SBS and microvillus inclusion disease (MVID) in the US, EU, and Middle East/North Africa regions, with results expected by the end of 2023 and in 2024. Crofelemer has been granted Orphan Drug Designation (ODD) by the FDA and the European Medicines Agency for both MVID and SBS with intestinal failure.
November 01, 2023 | 12:44 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The new patent issued to Jaguar Health strengthens its intellectual property protection for crofelemer, potentially increasing its market exclusivity and competitive advantage. This could positively impact the company's future revenues and profitability.
The issuance of a new patent for crofelemer strengthens Jaguar Health's intellectual property portfolio, potentially extending the drug's market exclusivity and providing a competitive advantage. This could lead to increased sales and profitability in the future, positively impacting the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100